ArticleScientific reports2025
Integrin linked kinase and threonine tyrosine kinase modulate TCR signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
T cell activation is critical for adaptive immunity, helping to protect the body from infection and tumors. A key step in this activation is signal transduction downstream of the T cell antigen receptor. This signaling involves several steps, with early ones occurring at the plasma membrane and others that occur later, after TCR internalization. The late steps in TCR signaling remain poorly understood. Since the TCR can signal after its internalization, we postulated that kinases abundantly expressed in T cells may regulate TCR signaling. This study focuses on two such enzymes: integrin-linked kinase (ILKs) and threonine-tyrosine kinase (TTKs), whose involvement in TCR signaling has not been previously studied. Using specific depletion of TTK and ILK by lentiviral shRNA, we show that in the absence of ILK and TTK, the early steps of TCR signaling are strongly enhanced, while IL-2 production by activated T cells is strongly decreased. These findings are relevant because TTK and ILK are both important targets in oncology, and our results show that their inhibition affects the activation of T cells, which play an essential role in anti-tumor defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.